KFDA rejects approval of Hanmi's sibutramine mesylate

Published: 2004-10-21 06:57:00

Updated: 2004-10-21 06:57:00

The Korea Food and Drug Administration reacted negatively toward the approval of Hanmi's first generic version of Slimer capsule (sibutramine mesylate), first generic version of Reductil (sibutramine hydrochloride), a type of anti-obesity medicine, saying that the original product has been under ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK